BMY vs CABA: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
BMY is the larger of the two ($126.33B market cap): the incumbent the market prices for continued execution (9.23x forward earnings, beta 0.19). CABA is the smaller challenger ($317.11M), priced similarly on forward earnings (-1.36x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
BMY vs CABA: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | BMY | CABA | What it tells you |
|---|---|---|---|
| Market cap | $126.33B | $317.11M | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 9.23 | -1.36 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 0.19 | 3.54 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 71% of range | 10% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 5.40 | 1.12 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how BMY and CABA affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and CABA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and CABA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Bristol Myers Squibb (BMY) do?
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is working through a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.
What does Cabaletta Bio (CABA) do?
Cabaletta Bio, Inc. (NASDAQ: CABA) is a clinical-stage biotechnology company focused on engineered T cell therapies for autoimmune disease. Its CABA (Cabaletta Approach to B cell Ablation) platform pursues the Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) approach, which uses CD19-directed CAR-T cells to deplete the B cells that drive autoimmune conditions, with the goal of a temporary but complete "immune system reset" rather than chronic suppression. The lead candidate, rese-cel (resecabtagene autoleucel, formerly CABA-201), is a fully human CD19-CAR T cell therapy.
BMY vs CABA: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- BMY drivers: New product portfolio ramp; Oncology and immunology depth.
- CABA drivers: Platform aimed at a large autoimmune market; Multi-indication RESET program.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For CABA, cABA is a speculative, pre-revenue clinical-stage stock whose value depends on trial readouts that could fail, slip, or underwhelm.
BMY or CABA: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; CABA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and CABA guides.
BMY vs CABA: the full fundamentals
BMY. At about $60.80 on October 16, 2026, Bristol Myers trades near 9 times forward earnings, still low relative to large-cap pharma peers, which reflects market skepticism about replacing patent-cliff revenue even after a 40% one-year rally. The 4.2% dividend yield and strong cash flow are the bull-case anchors, while consensus for roughly flat 2027 EPS (about $6.62 versus $6.65 for 2026) captures the bear case. The 24 analysts in Yahoo's consensus carry a mean target near $66, and Q3 2026 results arrive on October 29.
CABA. Cabaletta is pre-revenue, so price-to-earnings does not apply; it trades at about 1.2 times book value. With roughly $225 million of cash at the end of June plus about $115 million of warrant proceeds received since, the ~$248 million market value implies the market is assigning little or no value to the rese-cel pipeline itself. Management has noted going-concern considerations, and third-quarter results, expected around November 16, 2026 with consensus at a loss of $0.31 per share, should update cash and runway.
Headline figures (approximate, October 2026): BMY shows revenue (ttm) ~$49.2 billion (Q2 2026 up ~5.7% YoY), q2 2026 adjusted eps $2.04 vs $1.60 consensus, operating margin ~34%, net income (ttm) ~$9.3 billion; CABA shows share price ~$1.46 (October 16, 2026), the bottom of a ~$1.46-$4.23 52-week range, market capitalization ~$248 million, cash and debt ~$225 million cash at June 30, 2026, against ~$26 million debt, warrant proceeds ~$115 million received July 1 to September 12, 2026 (~$128 million total from June 2025 warrants).
The bottom line: BMY vs CABA
BMY and CABA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and CABA exposure against your real portfolio. It is not an investment adviser.
Wondering how BMY or CABA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Bristol Myers Squibb
Ask Walnut's AI anything about BMY and see how it fits what you own.
FAQ
What is the difference between BMY and CABA?
+
Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. Cabaletta Bio, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is BMY or CABA the better stock?
+
Neither is universally better. BMY is the larger incumbent; CABA is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, BMY or CABA?
+
On forward P/E (as of November 2026), BMY trades at 9.23x and CABA at -1.36x, so CABA is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both BMY and CABA?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of BMY vs CABA?
+
BMY: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. Revlimid has already declined under generic entry. The newer portfolio must scale fast enough to offset these losses, which is not guaranteed, and consensus already pencils in flat to lower revenue and EPS in 2027. Drug pricing pressure (including US Medicare negotiation under the Inflation Reduction Act, which named Eliquis), clinical trial failures, regulatory setbacks, and integration risk from large acquisitions all weigh on the outlook; the split admilparant readout in October 2026, which also came with protocol changes and a patient death the company said was likely unrelated, is a reminder of how quickly pipeline news can move the stock. Debt of about $45 billion against about $11 billion of cash, and litigation exposure, add further uncertainty. CABA: CABA is a speculative, pre-revenue clinical-stage stock whose value depends on trial readouts that could fail, slip, or underwhelm. The company has reported a going-concern consideration and relies on repeated equity raises and warrant exercises that dilute shareholders; tens of millions of new shares were issued in 2026 alone. Operating cash burn is running at roughly $154 million a year and the trailing net loss is about $181 million. It also competes in a crowded autoimmune cell-therapy field where rivals such as Kyverna are further along toward a first approval, which could affect positioning even if rese-cel succeeds. The stock fell about 43% in the month to October 16, 2026 to a 52-week low near $1.46, which shows how quickly sentiment can turn, and a single negative data point or financing setback can move it sharply again.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell BMY or CABA; figures are approximate and dated (as of November 2026). Verify current data before investing.